Hepatic copper concentrations approach or exceed 250 µ
g/g in untreated Wilson disease. Elevated hepatic copper is also seen with chronic biliary obstruction and cholestatic conditions. Results inconsistent with other findings may reflect heterogeneity in hepatic copper distribution.
Compliance Statement B
: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.